Loading provider…
Loading provider…
Rheumatology Physician in Los Angeles, CA
NPI: 1285655852Primary Practice Location
RONALD REAGAN UCLA MEDICAL CENTER
757 Westwood Plz, Los Angeles, CA
Primary Employer
UCLA Medical Plaza
uclahealth.org
HQ Phone
Get MD Maureen's Phone Numberphone_androidMobile
Get MD Maureen's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2001 - 2026
IL State Medical License
1997 - 2002
CA State Medical License

American Board of Internal Medicine
Rheumatology
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Rheumatology
2001 - 2003
Rush University Medical Center
Residency • Internal Medicine
1997 - 2001
Pritzker School of Medicine
pritzker.uchicago.edu
Medical School
Until 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 33 | 51 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 24 | 36 |
Authors: Deborah Mccurdy, Miriam Parsa, Alice Hoftman, Jennifer Grossman, Bevra Hahn
Journal: Arthritis Res Ther
Publication Date: 2013-01-23
Authors: Sangmee Bae, Jennifer Wang, Linh Truong, John Fitzgerald, Christina Charles-Schoeman, Howard Yang
Journal: Rheumatol Int
Publication Date: 2023-06-27
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
Authors: Daniel Furst, Dinesh Khanna
Publication Date: 2004-04
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Intervention / Treatment: BIOLOGICAL: BNT162b2, Bivalent, DRUG: Withhold IS (B cell depletion therapy), BIOLOGICAL: Ad26.COV2.S, BIOLOGICAL: Moderna mRNA-1273, BIOLOGICAL: BNT162b2, DRUG: Continue IS (MMF or MPA), DRUG: Continue IS (MTX), BIOLOGICAL: Continue IS (B cell depletion therapy), BIOLOGICAL: Monovalent [B.1.351] CoV2 preS dTM-AS03, DRUG: Withhold IS (MMF or MPA), DRUG: Withhold IS (MTX), BIOLOGICAL: Moderna mRNA-1273, Bivalent
Lead Sponsor: Northwell Health
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Intervention / Treatment: DRUG: Nelfinavir